The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a specific toxicity profile including skin toxicity. (Eur J Cancer)
Phase II trial examines quality of life with panitumumab-based intensified regimen
The CRC Digest